The Role of Serum Cytokeratin 19 Fragment in Transarterial Infusion against Invasive Bladder Cancer


Background: We used transcatheter arterial infusion chemotherapy (TAI) for patients with T1G3 and greater than T2 bladder cancer, which was diagnosed after extensive and deep transurethral resection of bladder tumor (TUR-BT), and we investigated the utility of serum cytokeratin 19 fragment (CYFRA) as a predictive factor of the response to therapy. Material and Methods: From November 2001 to November 2010, 56 patients (46 males and 10 females) with pathologically confirmed T1 G3 or greater than T2 bladder cancer after TUR-BT underwent two courses of TAI of cisplatin, methotrexate and doxorubicin as neoadjuvant setting. Then, patients underwent evaluation TUR-BT. Thereafter, the bladder was preserved in patients with superficial or undetectable tumors on TUR-BT. Advanced cases and residual bladder tumor cases were treated with total cystectomy or systemic chemotherapy. CYFRA levels were measured before and after performing TAI. Results: With this therapy, the 5-year survival rate was 85.7% in pT1G3, 82.3% in pT2, and 66.6% in greater than pT3 cases. Bladder preservation with no recurrence was observed in 58.7% of the patients. Grade III adverse events included leucopenia (6/56 patients: 10.7%). Serum CYFRA levels significantly decreased with treatment (in 4/6 patients with elevated CYFRA levels). Conclusion: These results suggest that although total cystictomy is usually indicated for T1G3 bladder cancers, bladder preservation and control of micrometastases can be achieved by performing TAI after extensive and deep TUR-BT. Our results also suggest the utility of monitoring serum CYFRA to assess the response to therapy.

Share and Cite:

R. Takahashi, R. Kimata, S. Nomura, I. Matsuzawa, Y. Suzuki, T. Hamasaki and Y. Kondo, "The Role of Serum Cytokeratin 19 Fragment in Transarterial Infusion against Invasive Bladder Cancer," Open Journal of Urology, Vol. 3 No. 3, 2013, pp. 160-164. doi: 10.4236/oju.2013.33030.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Y. Senga, G. Kimura, T. Hattori and K. Yoshida, “Clinical Evaluation of Soluble Cytokeratin 19 Fragments (CY-FRA 21-1) in Serum and Urine of Patients with Bladder Cancer,” Urology, Vol. 48, No. 5, 1996, pp. 703-710. doi:10.1016/S0090-4295(96)00253-1
[2] G. Gakis, J. Efstathiou, S. P. Lerner, et al., “ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder,” European Urology, Vol. 63, No. 1, 2013, pp. 45-57. doi:10.1016/j.eururo.2012.08.009
[3] H. Azuma, K. Yamamoto, T. Inamoto, et al., “Total Cystectomy versus Bladder Preservation Therapy for Locally Invasive Bladder Cancer: Effect of Combined Therapy Using Balloon-Occluded Arterial Infusion of Anticancer Agent and Hemodialysis with Concurrent Radiation,” American Journal of Clinical Oncology, Vol. 32, No. 6, 2009, pp. 592-606. doi:10.1097/COC.0b013e318199fb42
[4] H. Azuma, T. Inamoto, K. Takahara, et al., “Neoadjuvant and Adjuvant Chemotherapy for Locally Advanced Bladder Carcinoma: Development of Novel Bladder Preservation Approach, Osaka Medical College Regimen,” International Journal of Urology, Vol. 19, No. 1, 2012, pp. 26-38. doi:10.1111/j.1442-2042.2011.02856.x
[5] H. Azuma, T. Inamoto, N. Ibuki, et al., “Novel Bladder Preservation Therapy for Locally Invasive Bladder Cancer: Combined Therapy Using Balloon-Occluded Arterial Infusion of Anticancer Agent and Hemodialysis with Concurrent Radiation,” International Journal of Urology, Vol. 37, No. 4, 2010, pp. 773-785. doi:10.3892/ijo_00000727
[6] A. Mokarim, M. Uetani, I. Sakamoto, et al., “Transcatheter Arterial Infusion of Cisplatin and Doxorubicin in Bladder Cancer,” Acta Oncologica, Vol. 36, 1997, pp. 175-181. doi:10.3109/02841869709109227
[7] S. Ozono, S. C. Kim, K. Takashima, et al., “Intra-Arterial Chemotherapy for Invasive Bladder Cancer,” Hinyokika Kiyo, Vol. 45, No. 2, 1999, pp. 133-137.
[8] H. J. Yan, R. B. Wang, K. L. Zhu, et al., “Cytokeratin 19 Fragment Antigen 21-1 as an Independent Predictor for Definitive Chemoradiotherapy Sensitivity in Esophageal Squamous Cell Carcinoma,” Chinese Medical Journal (English Edition), Vol. 125, No. 8, 2012, pp. 1410-1415.
[9] Y. N. Fahmueller, D. Nagel, R. T. Hoffmann, et al., “Predictive and Prognostic Value of Circulating Nucleosomes and Serum Biomarkers in Patients with Metastasized Colorectal Cancer Undergoing Selective Internal Radiation Therapy,” BMC Cancer, Vol. 4, No. 12, 2012, p. 5.
[10] W. Sidney, P. C. Vincent, S. Melvin and J. Douglas, “Transcatheter Intraarterial Infusion of Chemotherapy in Advanced Bladder Cancer,” Cancer, Vol. 49, 1982, pp. 640-645. doi:10.1002/1097-0142(19820215)49:4<640::AID-CNCR2820490406>3.0.CO;2-6
[11] C. Andreadis, S. Touloupidis, G. Galaktidou, et al., “Serum CYFRA 21-1 in Patients with Invasive Bladder Cancer and Its Relevance as a Tumor Marker during Chemotherapy,” Journal of Urology, Vol. 174, No. 5, 2005, pp. 1771-1775. doi:10.1097/01.ju.0000176742.53556.25

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.